Stock Price Prediction

RNXT stock has a bullish outlook with a price target of $9, as maintained by Ascendiant Capital analyst Edward Woo on December 10, 2024. The optimism stems from the ongoing commercialization of RenovoCath and its potential to address unmet needs in oncology and interventional radiology. Additionally, the TIGeR-PaC Phase III study could further enhance investor confidence if successful.

RNXT stock currently trades at $1.05, significantly below its recent analyst price target of $9, reflecting bearish sentiment. The lack of revenue generation, despite meeting EPS expectations (-$0.10), raises concerns about its financial sustainability. Additionally, its reliance on the commercialization of RenovoCath and ongoing clinical trials introduces high execution risk.